Hello

Ghada Ismail

Founded in 2006 in San Marino, Bioscience Institute has grown into a leading name in regenerative medicine and genomics, with key operations in Europe and the Middle East. The company was the first to establish a private stem cell lab in the GCC, launching a state-of-the-art Cell Factory and Biobank in Dubai.

Known for its strong focus on research and innovation, Bioscience works closely with top universities and reinvests in developing advanced therapies. As it looks to expand further into the Gulf, particularly Saudi Arabia, the company is bringing its expertise in stem cells, personalized medicine, and AI-powered diagnostics to the region.

In this interview, we explore how Bioscience built credibility in a new field, how it views the Saudi market, and what’s next for its growth in the GCC.

You launched the first private stem cell lab in the GCC back in 2013. What was the regional and global landscape for stem cell therapy like at the time, and how did you establish scientific credibility in such an emerging field?

When we began our stem cell cultivation activity in Dubai in 2013, we built a cell factory that was the only one of its kind in the entire Middle East. At the time, there were only about a hundred clinical trials underway, whereas now there are more than 1,600. Back then, there were no authorizations from the FDA or the European Medicines Agency, whereas now such approvals exist. Scientific evidence was limited to a few localized treatments, whereas today systemic physiopathological and pathological conditions are being treated with excellent results. Scientific evidence and our rigorous activity have contributed to building our credibility in the region.

Bioscience has been operating across Europe and the UAE. What draws you to Saudi Arabia now, and how do you view its potential for knowledge transfer and long-term collaboration?

We are very interested in what is happening in KSA and in the opportunity to export our know-how, which began to take shape in 2007 when we started our operations in Italy. For this to happen, it will be necessary to share our experience with a Saudi partner who is suitable in terms of expertise and capabilities.

How would you describe the regulatory and cultural environment in the GCC when it comes to adopting advanced biomedical technologies like stem cell therapy?

The regulatory and cultural environment of the GCC has been open to dialogue and has not taken a prejudiced stance. As a result, it focuses on the substance of proposals, facilitating the introduction of innovative technologies in the region more quickly than in other countries. The GCC regulatory framework is highly flexible and is not influenced by the lobbying of large industries, as is often the case in the USA and Europe.

How is Bioscience leveraging AI to support clinical decision-making and improve patient outcomes, especially as the company expands into more complex markets like Saudi Arabia?

We use AI for our Clinical Decision Support System, which assists our physicians in performing accurate patient assessments and identifying the most suitable therapy by cross-referencing data from numerous biomarkers—something that would otherwise be impossible for a human to achieve.

With digital transformation reshaping patient expectations in Saudi Arabia, how is Bioscience adapting its technology and service models to meet demand for more personalized and tech-enabled care?

We have developed an IT platform that functions as an operating system and can be integrated into the operations of any clinic, enabling the use of the most advanced protocol in the fields of molecular biology, genomics, and regenerative medicine with stem cells and exosomes.

Given Saudi Arabia’s growing investment in biotech and innovation, do you see the Kingdom emerging as a regional R&D hub for regenerative medicine in the coming years?

Saudi Arabia has the potential to become a hub for R&D in regenerative medicine; however, in addition to investments, a supportive environment and incentives should be created for companies with know-how that could be shared.

Ghada Ismail

Founded in 2006 in San Marino, Bioscience Institute has grown into a leading name in regenerative medicine and genomics, with key operations in Europe and the Middle East. The company was the first to establish a private stem cell lab in the GCC, launching a state-of-the-art Cell Factory and Biobank in Dubai.

Known for its strong focus on research and innovation, Bioscience works closely with top universities and reinvests in developing advanced therapies. As it looks to expand further into the Gulf, particularly Saudi Arabia, the company is bringing its expertise in stem cells, personalized medicine, and AI-powered diagnostics to the region.

In this interview, we explore how Bioscience built credibility in a new field, how it views the Saudi market, and what’s next for its growth in the GCC.

You launched the first private stem cell lab in the GCC back in 2013. What was the regional and global landscape for stem cell therapy like at the time, and how did you establish scientific credibility in such an emerging field?

When we began our stem cell cultivation activity in Dubai in 2013, we built a cell factory that was the only one of its kind in the entire Middle East. At the time, there were only about a hundred clinical trials underway, whereas now there are more than 1,600. Back then, there were no authorizations from the FDA or the European Medicines Agency, whereas now such approvals exist. Scientific evidence was limited to a few localized treatments, whereas today systemic physiopathological and pathological conditions are being treated with excellent results. Scientific evidence and our rigorous activity have contributed to building our credibility in the region.

Bioscience has been operating across Europe and the UAE. What draws you to Saudi Arabia now, and how do you view its potential for knowledge transfer and long-term collaboration?

We are very interested in what is happening in KSA and in the opportunity to export our know-how, which began to take shape in 2007 when we started our operations in Italy. For this to happen, it will be necessary to share our experience with a Saudi partner who is suitable in terms of expertise and capabilities.

How would you describe the regulatory and cultural environment in the GCC when it comes to adopting advanced biomedical technologies like stem cell therapy?

The regulatory and cultural environment of the GCC has been open to dialogue and has not taken a prejudiced stance. As a result, it focuses on the substance of proposals, facilitating the introduction of innovative technologies in the region more quickly than in other countries. The GCC regulatory framework is highly flexible and is not influenced by the lobbying of large industries, as is often the case in the USA and Europe.

How is Bioscience leveraging AI to support clinical decision-making and improve patient outcomes, especially as the company expands into more complex markets like Saudi Arabia?

We use AI for our Clinical Decision Support System, which assists our physicians in performing accurate patient assessments and identifying the most suitable therapy by cross-referencing data from numerous biomarkers—something that would otherwise be impossible for a human to achieve.

With digital transformation reshaping patient expectations in Saudi Arabia, how is Bioscience adapting its technology and service models to meet demand for more personalized and tech-enabled care?

We have developed an IT platform that functions as an operating system and can be integrated into the operations of any clinic, enabling the use of the most advanced protocol in the fields of molecular biology, genomics, and regenerative medicine with stem cells and exosomes.

Given Saudi Arabia’s growing investment in biotech and innovation, do you see the Kingdom emerging as a regional R&D hub for regenerative medicine in the coming years?

Saudi Arabia has the potential to become a hub for R&D in regenerative medicine; however, in addition to investments, a supportive environment and incentives should be created for companies with know-how that could be shared.

<body>
   <h1>Welcome to My Website</h1>
   <p>This is a simple HTML page.</p>
   <button onclick="alert('Hello!')">Click Me</button>
</body>

As organizations across the MEA region increasingly embrace digitalization strategies and rapidly shift toward cloud migration, we will inevitably see an expansion of the threat surface area. The region has already witnessed exponential growth in threats such as DDoS attacks, phishing, and ransomware, resulting in the implementation of strict regulatory compliance measures across many countries and greater awareness around the need for organizations to improve their security postures. This will drive strong demand for security solutions over the next few years until the situation stabilizes.